In addition to being recognized for its outstanding clinical care, UCLA Health also houses a premier research institution, so you may be asked to participate in one or several studies. These studies are only allowed if the Institutional Review Board, the Office of the Human Research Protection Program and the National Institute of Health (if federally funded) believe the benefits outweigh the risks. These studies have many safeguards and require best-care practices. Please feel free to ask if you or your loved one might qualify. These studies are voluntary, but could be beneficial as study participants are closely monitored by another team of healthcare professionals including other physicians and nurses.
Prevention and early treatment of acute lung injury (PETAL) network. PETAL network website >
Vitamin C, Thiamine, and Steroids in Sepsis (VICTAS). VICTAS study website >
VICTAS is a clinical trial testing the combination of vitamin C, thiamine and hydrocortisone for the treatment of sepsis, a life-threatening condition caused by a severe infection. Sepsis is the most common cause for admission to an intensive care unit. Preliminary research suggests that this combination of medications may reduce damage to major organs and increase the likelihood of surviving a severe episode of sepsis. VICTAS is a multicenter, randomized controlled trial whose objective is to further examine the impact of this combination of medications on patients with sepsis (completed enrollment)
Discovery, the Critical Care Research Network
Formed under the auspices of the SCCM by merging the United States Critical Illness and Injuries Trials (USCIIT) and the Critical Care Pharmacotherapy Trials Network (CCPTN). SCCM website >
Ethics in the critical care setting
Care for the critically ill is complex, dynamic, and resource-intensive. Knowing when patients are too ill to benefit from intensive care is essential for the clinician to guide patients and families toward aggressive care when it might be helpful and toward palliative care when it is not. Research is being performed to understand the barriers to appropriate palliative care in the ICU and to better match the aggressiveness of care to prognosis.
Critical care ultrasound evaluation of fluid responsiveness in the shock states – carotid flow-time evaluation
Sponsor: GE Healthcare
This project tested the applicability of bedside ultrasound in the assessment of fluid responsiveness in spontaneously breathing and mechanically ventilated patients. Change in carotid flow and change in carotid time flow were assessed prior, after maneuver (passive leg raise), before, and after fluid bolus. The response was compared to NICOM bioreactance fluid responsiveness monitor. Data on pulmonary B-line quantification, an ultrasound assessment of extravascular lung water in fluid resuscitation, was also collected (completed enrollment). Read full article >
Airway database: review of MICU intubations - hypoxemic respiratory failure and in acute right heart failure (with feasibility of Non-invasive ventilation (BiPAP) supported bronchoscopic endotracheal intubation)
Transition to mechanical ventilation in severely sick patients (severely hypoxemic, NIV-dependant, in right heart failure) carries a high-risk of complications and further clinical deterioration. Over the past several years, we have gained experience in bronchoscopic intubaton and have published our experience using BiPAP as a tool to support prior and during intubatation, potentially reducing risks of desaturation, derecruitment and hemodynamic swings in transition from negative to positive pressure ventilation. Read full article > We have also published our data about the use of awake fiberoptic intubation in severe pulmonary hypertension and suspected right heart failure. Read full article >
High output shock that is unresponsive to catecholamine and vasopressin support has a high mortality. ATHOS3 was a Phase III trial that showed that Angiotensin II, an agent that acts through a pathway distinct from catecholamines and vasopressin, could successfully support blood pressure without a need for increasing background vasoactive agents. This trial resulted in FDA-approval of Angiotensin II for vasoactive support in high-output shock. Read full article >
3 Wishes Project
Started in December 2017, the “3 Wishes Project” is a pilot research intervention which aims to elicit and implement wishes that are unique to each dying patient and their loved ones. The goal of the 3 Wishes Project is to provide the best possible end-of-life experience for patients and families by celebrating the life of those who are dying and supporting those who are grieving. This intervention has been performed at McMaster University in Canada and proven to be highly successful in improving the bereavement process for family members as well as the professional morale of the healthcare team. Evaluation of the MICU pilot is underway and based on what we learn, we hope to improve, sustain, and expand the 3 Wishes intervention. Learn more >